🔴 Neurosense Therapeutics is trading 10% down today — no verified company-specific catalyst

Neurosense Therapeutics is trading 9.94% lower at $2.40, with no verified company-specific catalyst for the October 20 decline.

• The company’s October 19 announcement was a U.S. patent application for potential PrimeC use in traumatic brain injury—not an issued patent or approval—and available reporting does not link it to the decline.
• The biotech sector is up 2.10%, unlike the stock’s move.
• Shares also fell 13.19% on October 19; no reliable volume information was available.